All Updates

All Updates

icon
Filter
M&A
Click Therapeutics acquires assets of Better Therapeutics for undisclosed sum
Mental Health Tech
May 22, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Mental Health Tech

Mental Health Tech

May 22, 2024

Click Therapeutics acquires assets of Better Therapeutics for undisclosed sum

M&A

  • Click Therapeutics, a mental-health-focused digital therapeutics provider, has acquired the assets of cardiometabolic digital therapeutic provider Better Therapeutics for an undisclosed sum. The assets acquired include Better Therapeutics' FDA-authorized prescription digital therapeutic for type 2 diabetes (AspyreRx - BT-001) and other assets related to the treatment of obesity, hypertension, and hyperlipidemia.

  • With the acquisition of Better Therapeutics' assets, Click Therapeutics plans to bolster its development efforts in obesity and cardiometabolic diseases. It aims to fuse AspyreRx's clinically validated digital behavioral therapy with Click's AI-enabled platform to enhance patient care and provider capabilities. Click Therapeutics believes that its drug-software combination products can elevate patient care, improve clinical outcomes, and deliver valuable real-world data insights for providers and payers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.